This page will host Events plug-in for all Clarion and trade events.

Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lobe Sciences Ltd (CSE:LOBE)

0.1100 UNCHANGED
Streaming Delayed Price Updated: 3:39 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1100
Bid (Size) 0.1000 (5,000)
Ask (Size) 0.1300 (13,000)
Prev. Close 0.1100
Today's Range 0.1100 - 0.1100
52wk Range 0.0200 - 0.1350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services
Via ACCESS Newswire

Performance

YTD
+120.0%
+120.0%
1 Month
+57.1%
+57.1%
3 Month
+83.3%
+83.3%
6 Month
+175.0%
+175.0%
1 Year
+214.3%
+214.3%

More News

Read More
News headline image
Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update
Via ACCESS Newswire
News headline image
Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Via ACCESS Newswire
News headline image
Lobe Sciences Reports First Quarter 2026 Results and Highlights
Via ACCESS Newswire
News headline image
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
Via ACCESS Newswire
News headline image
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
Via ACCESS Newswire
News headline image
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
Via ACCESS Newswire
News headline image
Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
Via ACCESS Newswire
News headline image
Lobe Sciences Improves Balance Sheet
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025
Via ACCESS Newswire
News headline image
Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors
Via ACCESS Newswire
News headline image
Lobe Sciences Announces the Closing of the Previously Announced Private Placement
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Debt Settlement
Via ACCESS Newswire
News headline image
Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
Via ACCESS Newswire
News headline image
Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
Via ACCESS Newswire
News headline image
Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
Via ACCESS Newswire
News headline image
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
Via ACCESS Newswire
News headline image
Lobe Sciences Provides Corporate Update
Via ACCESS Newswire
News headline image
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
From Lobe Sciences Ltd.
Via Business Wire
News headline image
Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
From Lobe Sciences, Ltd.
Via Business Wire
News headline image
Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
From Lobe Sciences, Ltd.
Via Business Wire

Frequently Asked Questions

Is Lobe Sciences Ltd publicly traded?
Yes, Lobe Sciences Ltd is publicly traded.
What exchange does Lobe Sciences Ltd trade on?
Lobe Sciences Ltd trades on the Canadian Securities Exchange
What is the ticker symbol for Lobe Sciences Ltd?
The ticker symbol for Lobe Sciences Ltd is LOBE on the Canadian Securities Exchange
What is the current price of Lobe Sciences Ltd?
The current price of Lobe Sciences Ltd is 0.1100
When was Lobe Sciences Ltd last traded?
The last trade of Lobe Sciences Ltd was at 04/27/26 03:39 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.